Centogene Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Centogene şirketinin kazançları yıllık ortalama -18% oranında azalırken, Healthcare sektörünün kazançları yıllık 5.4% oranında artan oldu. Gelirler yıllık ortalama 0.8% oranında artan oldu.

Anahtar bilgiler

-18.0%

Kazanç büyüme oranı

-9.8%

EPS büyüme oranı

Healthcare Sektör Büyümesi	8.5%
Gelir büyüme oranı	0.8%
Özkaynak getirisi	n/a
Net Marj	-73.2%
Son Kazanç Güncellemesi	31 Dec 2023

Yakın geçmiş performans güncellemeleri

Recent updates

Take Care Before Jumping Onto Centogene N.V. (NASDAQ:CNTG) Even Though It's 36% Cheaper

Aug 06

Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Feb 16

Gelir ve Gider Dağılımı

Centogene nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OTCPK:CNTG.F Gelir, gider ve kazançlar (EUR Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Dec 23	49	-36	46	12
30 Sep 23	50	-38	45	14
30 Jun 23	51	-40	45	15
31 Mar 23	49	-40	44	16
31 Dec 22	47	-39	42	17
30 Sep 22	-15	-44	46	20
30 Jun 22	2	-58	49	20
31 Mar 22	190	-44	55	20
31 Dec 21	42	-57	54	19
30 Sep 21	162	-40	59	17
30 Jun 21	168	-24	57	18
31 Mar 21	126	-27	55	17
01 Jan 21	38	-60	49	15
30 Sep 20	73	-30	43	14
30 Jun 20	49	-28	39	11
31 Mar 20	50	-24	35	11
31 Dec 19	49	-21	33	10
30 Sep 19	44	-19	30	9
30 Jun 19	45	-16	30	8
31 Mar 19	43	-13	28	7
31 Dec 18	40	-11	26	6
30 Sep 18	39	-9	23	7
31 Dec 17	32	-5	15	6
31 Dec 16	28	-5	14	6

Kaliteli Kazançlar: CNTG.F şu anda kârlı değil.

Büyüyen Kar Marjı: CNTG.F şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: CNTG.F kârlı değildir ve zararlar son 5 yılda yılda 18% oranında artmıştır.

Büyüme Hızlandırma: CNTG.F 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: CNTG.F kârlı olmadığından, geçmiş yıl kazanç büyümesinin Healthcare sektörüyle ( 10.1% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: CNTG.F 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

Centogene Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2022 earnings: EPS exceeds analyst expectations

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings: EPS and revenues exceed analyst expectations

Second quarter 2021 earnings released: €0.37 loss per share (vs €0.52 loss in 2Q 2020)

Recent updates

Centogene N.V. Announces Term Expires of Jose Miguel Coego Rios as Chief Financial Officer

Centogene N.V Announces Data from the Rostock International Parkinson's Disease (ROPAD)

Centogene Receives Delisting Notice from Nasdaq, Effective at the Open of Trading on August 8, 2024

Take Care Before Jumping Onto Centogene N.V. (NASDAQ:CNTG) Even Though It's 36% Cheaper

Centogene Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors

Centogene N.V. Provides Earnings Guidance for the Year 2024

Centogene Biodatabank Grows to Incorporate Disease Insights from over 850,000 Diverse Patients

Centogene N.V. announced delayed 20-F filing

New minor risk - Financial data availability

Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Centogene N.V. Provides Earnings Guidance for the Full Year 2023

Centogene N.V. (NASDAQ:CNTG) Might Not Be As Mispriced As It Looks

Centogene N.V. Announces Changes to Supervisory Board

Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

Centogene N.V. Announces the Discovery of A New Form of Early-Onset Dystonia and Parkinsonism

Centogene N.V. Expands Multiomic Diagnostic Portfolio with Newly-Launched Transcriptomic Offering

New major risk - Revenue and earnings growth

Centogene N.V. Reaffirms Revenue Guidance for the Year 2023

Centogene N.V. Announces Publication Establishing Lyso-Gb1 as A Predictive Biomarker for Gaucher Disease Patients

Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board

Centogene Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort

Centogene N.V. announced that it expects to receive $30 million in funding from Lifera

New minor risk - Shareholder dilution

Centogene Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

Centogene N.V., Annual General Meeting, Jun 30, 2023

Centogene N.V., Annual General Meeting, Jun 30, 2023

Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Centogene N.V. Provides Revenue Guidance for Fiscal Year 2023

Centogene Regains Compliance with Nasdaq Listing Requirements

Centogene N.V. Appoints Prof. Peter Bauer, Chief Medical and Genomic Officer to its Management Board and as Managing Director of the subsidiary Centogene GmbH

Centogene N.V. Announces Resignation of Florian Vogel as Chief Process Officer, Effective February 28, 2023

Twist Bioscience and Centogene Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Centogene N.V. Provides Revenue Guidance for the Fiscal Year 2022

Centogene Receives Nasdaq Non-Compliance Notice

Centogene N.V. Announces Changes to Supervisory Board

Centogene Launches Rare and Neurodegenerative Disease Biodata Network

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Centogene N.V. Reaffirms Earnings Guidance for the Year 2022

Centogene GAAP EPS of -€0.28, revenue of €10.32M

Centogene N.V. Announces Appointment of Miguel Coego Rios as Managing Director

Centogene N.V., Annual General Meeting, Jun 22, 2022

Centogene N.V., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Centogene N.V. Provides Earnings Guidance for the Year 2022

Centogene N.V. Appoints Miguel Coego Rios as Executive Vice President of Finance & Legal

Centogene N.V. announced that it has received €14.915363 million in funding from DPE Deutsche Private Equity GmbH, TVM Life Science Management Inc, Careventures S.A.

Centogene N.V. Announces the Global Release of CentoCloud, A SaaS Platform Enabling Decentralized Analysis, Interpretation, and Reporting of Genomic Variants Linked to Rare Diseases

Third quarter 2021 earnings: EPS and revenues exceed analyst expectations

Centogene N.V. Provides Earnings Guidance for the Full Year 2021

Consensus forecasts updated

Is Centogene (NASDAQ:CNTG) Using Debt In A Risky Way?

Second quarter 2021 earnings released: €0.37 loss per share (vs €0.52 loss in 2Q 2020)

Centogene N.V. Provides Revenue Guidance for the Second Half and Full Year of 2021

Chief Scientific Officer Philip Lambert has left the company

Executive Officer Richard Stoffelen has left the company

Is Centogene (NASDAQ:CNTG) Using Debt Sensibly?

Consensus forecasts updated

First quarter 2021 earnings released: €0.22 loss per share (vs €0.43 loss in 1Q 2020)

Centogene N.V. Announces Unaudited Consolidated Impairment Charges for the First Quarter Ended March 31, 2021

Centogene reports Q1 results

Centogene N.V. Initiates EFRONT Study to Identify Patients with Genetic Forms of Frontotemporal Dementia

Centogene N.V. Launches New CentoXome

Centogene, Alector initiate EFRONT study in frontotemporal dementia

Centogene to nominate Rene Just as CFO at the upcoming Annual General Meeting

Centogene N.V. Extends Global Parkinson’s Disease Study

Centogene N.V. Releases Centomd® 6.0 – the Company’s Rare Disease Database Powered by Its Bio/Databank